Efficacy and Safety of Xylometazoline-Based Nasal Sprays with and Without Lysozyme in the Treatment of Acute Nasopharyngitis

Lysozyme in treatment of nasopharyngitis

Abstract

Background: Acute nasopharyngitis is a common condition usually accompanied by nasal congestion. The aim of this study was to compare efficacy and safety of a spray containing xylometazoline and lysozyme with a spray containing only xylometazoline in the treatment of acute nasopharyngitis.

Methods: A prospective, comparative, post-marketing study was performed on subjects with acute nasopharyngitis divided into xylometazoline+lysozyme or xylometazoline nasal spray groups. Data collection was performed at baseline before treatment, 30 minutes after treatment and at seven-day follow-up.

Main findings: Out of 173 included subjects, 59 were in the xylometazoline+lysozyme and 114 in the xylometazoline group. In both groups nasal patency was significantly improved 30 minutes after the therapy application (p<0.001). In the xylometazoline+lysozyme group, all subjects had nasal decongestion within 20 minutes and this was significantly quicker (p=0.037) than the xylometazoline group, where 16 subjects (14%) needed 20 to 120 minutes for nasal decongestion. All adverse events were mild and there was no significant difference in the number of adverse events between the groups.

Principal conclusions: Nasal sprays containing xylometazoline with or without lysozyme were effective and safe in the treatment of acute nasopharyngitis. The spray containing xylometazoline with lysozyme showed a faster effect with significantly shorter time to nasal decongestion. All recorded adverse events were mild and there was no difference between the groups in the number of recorded adverse events.